In connection with the move, the Clearwater, Fla.-based company said that it is shifting its stock exchange listing from the New York Stock Exchange to the NASDAQ Global Select Market. The company plans to trade under the new ticker symbol, “APYX”, beginning January 2.
In August, Bovie dealt its core business, including the Bovie brand, to Symmetry Surgical for $97 million. The all-cash sale augured a pivot for Bovie toward the cosmetic surgery market with its J-Plasma and Renuvion brands.
“We are pleased to join the world’s most innovative and growth-oriented companies listed on NASDAQ and are excited to partner with NASDAQ to leverage trading liquidity, enhanced visibility for issuers, leading technology and cost efficiencies. We also announced a corporate rebranding and company name change to Apyx Medical Corporation which is the final milestone resulting from the previously announced divestiture and sale of the core business segment and Bovie brand to Symmetry Surgical, Inc. The new name and brand emphasizes the company’s goal to be the most innovative, customer and solution focused company in the cosmetic surgery market and the broader medical technology sector. Apyx Medical Corporation endeavors to reshape the cosmetic surgery market by providing unique and creative solutions for the ever-changing needs of our physician customers and their patients,” prez & CEO Charlie Goodwin said in a prepared statement.
In September, Bovie Medical, fresh from the sale of its core electro-cautery business, saw its share price take a hit after it updated its outlook for the rest of the year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.